Johnson & Johnson announced a new Moisture Retention Index showing clear differences among seven daily disposable silicone hydrogel contact lenses. Other studies being showcased include a survey of U.S. female eyecare professionals, linking presbyopia with perimenopause and patient-reported satisfaction for ACUVUE VITA reusable contact lenses. The data will be presented at the American Academy of Optometry’s annual meeting in Anaheim, California.
“New data illustrates the superior advantages of our ACUVUE OASYS MAX 1-Day and ACUVUE OASYS 1-Day Contact Lens technology vs. competitive technology. The findings distinctly highlight the positive impact our lens technology has on patients’ vision, reaffirming our leadership in material sciences and contact lens innovation,” said Dr. Caroline Blackie, Vice President of Medical Affairs, Vision, MedTech, Johnson & Johnson.
Researchers tested seven daily disposable silicone hydrogel contact lenses to see how well each one resisted water evaporation by using a new Moisture Retention Index, a measure of how much a lens slows evaporation compared with saline, at 35°C and 40% humidity. The study found clear differences between products with ACUVUE OASYS MAX 1‑Day having the highest moisture retention index, followed by ACUVUE OASYS 1‑Day. The Moisture Retention Index could help link lens comfort and end‑of‑day dryness to material properties like polymer composition and how water is held in the lens.
Among the fifteen accepted abstracts, other highlights include:
Perceptions of Linking Presbyopia with Perimenopause: A Survey of U.S. Female Eye Care Professionals – Bishop et al.
- A survey of 75 U.S. female optometrists found that many patients experience emotional reactions when presbyopia starts—about two-thirds of clinicians said patients often show feelings like “too young for this” (45%) or frustration (41%)—and more than half reported patients also bring up other symptoms such as dry eye, headaches, or perimenopausal/menopausal issues.
- Most clinicians (76%) see presbyopia and midlife hormonal symptoms occurring at the same time, but over half don’t bring up broader health topics during visits because of time limits, uncertainty, or discomfort.
-
Almost all respondents (91%) thought patients would welcome combined information on vision changes and menopause, pointing to a clear opportunity for simple, trustworthy educational resources and more empathetic conversations that link presbyopia with women’s midlife health.
Patient-Reported Vision, Handling, and Comfort with Senofilcon C Reusable Lens – Osei et al.
- Over four weeks, 80 healthy, habitual soft contact lens wearers aged 18-40 years (mean age: 30.6 years) wore ACUVUE VITA reusable contact lenses and reported their experiences with comfort, vision, and handling.
-
Nearly 9 in 10 wearers reported that the lenses felt comfortable and smooth.
-
Nearly 9 in 10 wearers were satisfied with clarity of vision throughout the day and reported very good vision at the end of the day.
-
9 in 10 wearers found the lenses easy to insert and remove, while 8 in 10 rated lens handling as exceptional.
-
Overall, the findings highlight the ability of ACUVUE VITA to support a seamless and satisfying contact lens experience throughout everyday wear.
To learn more about ACUVUE or to search for an eyecare provider, visit https://www.ACUVUE.com/en-us.
Important Information for Contact Lens Wearers: ACUVUE® Contact Lenses are available by prescription only for vision correction. An eye care professional will determine whether contact lenses are right for you. Although rare, serious eye problems can develop while wearing contact lenses. To help avoid these problems, follow the wear and replacement schedule and the lens care instructions provided by your eye doctor. Do not wear contact lenses if you have an eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. If one of these conditions occurs, remove the lens and contact your eye doctor immediately. For more information on proper wear, care and safety, talk to your eye care professional and ask for a Patient Instruction Guide, call 1-800-843-2020, or download the Patient Instruction Guide.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to ACUVUE OASYS MAX 1‑Day, ACUVUE OASYS 1‑Day, and ACUVUE VITA. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at https://www.sec.gov, http://www.jnj.com/, http://www.investor.jnj.com/ or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
